

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Sub: Outcome of Board Meeting under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")


Pursuant to Regulations 30 of the SEBI Listing Regulations, Board of Directors in its meeting held on Thursday, November 10, 2022 ("Meeting"), inter alia, considered and approved following business:


- i. Un-Audited Standalone and Consolidated Financial Results for half year ended September 30, 2022.
- ii. Declaration of Dividend of Rs. 0.25 per share {2.5% per share} for FY 2022-23, Record date is fixed as Friday, 18th November 2022 for the purpose of payment of interim Dividend.
- iii. Approval of Business setup in Dubai by incorporating a new companies and Power of attorney to be executed in favour of Dr. Rohit Madhav Sane, Managing Director & CEO of the Company.
- iv. Approval to form a subsidiary company with name "F-Health Accelerators Private Limited" {subject to availability of names} to incubate/nurture/promote healthcare and healthcare related ventures.
- v. Approval of Statement of Deviation(s) and Variation(s) for period ended 30th September 2022

The Board Meeting was commenced on 12.00 Noon and concluded on 2.30 pm

We would request you to take the above intimation on records.

For; Vaidya Sane Ayurved Laboratories Limited


Abhishek Deshpande
Company Secretary & Compliance Officer



VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:

FL.5 1047, Shriram Bhawan, Shukrawar Peth,
Pune- 411002, Maharashtra India.
CIN No : L73100PN1999PLC013509

Corporate Office Address:

Ishan Bldg. No. 2, 701, 7th Floor, Gokhale Road, Naupada,
Thane (W)-400 602. Tel: +91 022-41235315/16
www.madhavbaug.org



A. A. MOHARE & CO.
CHARTERED ACCOUNTANTS

1/3, Shree Vivekanand CHS Ltd.,
Guru Mandir Road, Saraswat Colony,
Dombivli (East) 421 201.
M : 9223 543 842 / LL : 0251 - 2473000
Email : amit@aamco.in


**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO
THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTORIES LIMITED**


To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **VAIDYA SANE AYURVED LABROTORIES LIMITED** (the "Company"), for the half year ended September 30, 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Standalone Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at September 30, 2022, and of its results of operations and its Standalone cash flows for the half year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed.

For A A Mohare & Co.
Chartered Accountants (FRN : 114152W)


CA Amit A Mohare
Partner



Membership No. : 148601
Place : Thane
Date : 10/11/2022
UDIN : 22148601BCRWRL5094

Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)

F/ No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Statement of profit and loss for the Half year ended September 30, 2022

Particulars	(Rupees in Lakhs)		
	For the year ended September 30, 2022 Unaudited	For the year ended September 30, 2021 Unaudited	For the year ended March 31, 2022 Audited
Revenue			
Revenue from operations	4,552.73	3136.17	7471.05
Other income	82.51	0.10	33.87
Total revenue	4,635.23	3136.27	7504.93
Expenses			
Purchases of stock-in-trade	1,310.87	967.59	2195.18
Change in inventory of finished goods, WIP and traded goods	(4.42)	32.72	11.43
Employee benefit expenses	1,071.63	900.96	1817.72
Finance costs	11.30	10.88	20.18
Depreciation and amortisation expense	115.53	117.45	228.57
Other expenses	1,729.99	973.96	2755.46
Total expenses	4,234.90	3003.55	7028.54
Profit / (loss) before prior period adjustments & tax.	400.33	132.72	476.39
Prior period adjustments	-	0.00	1.49
Profit / (loss) before extraordinary items and tax	400.33	132.72	474.89
Extraordinary items	-	0.00	0.00
Profit / (loss) before tax	400.33	132.72	474.89
Tax expense			
Current tax	99.30	17.25	119.14
Deferred tax (expense)/income	(0.08)	(20.01)	8.85
Profit for the year	301.11	135.47	346.89
Earnings per equity share			
(Nominal value per share Rs. 10 (PY. 2021-22 - Rs.10))			
Basic	2.86	1.94	8.00
Diluted	2.86	1.94	8.00

Notes :

- 1) The above financial results for the half year ended September 30, 2022 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 10th NOV, 2022
- 2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid un-audited financial results for the half year ended 30th SEP 2022, which were also approved by the Audit Committee and Board at their meeting held on Thursday, 10th NOV, 2022.
- 3) The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- 4) As per MCA Notification Dated 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category. It has not adapted IND-AS for preparation of financial results.
- 5) The company has issued and allotted 27,71,200 equity share having face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below.


Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	838.08	761.92
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1211.06	761.92

As per our report on even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)


Amit Mohare
Amit Mohare
Partner
Membership No. 148601
Place : Thane
Date : 10/11/2022
UDIN : 22148601BCRWRL5094



For Vaidya Sane Ayurved Lab Limited

Rohit Sane
Rohit Sane
MD & CEO
DIN: 00679851

Place : Thane
Date : 10/11/2022



Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Balance sheet as at 30-Sep-2022


(Rupees in Lakhs)

	As at 30-Sep-22	As at 30-Sep-21	As at 31-Mar-22 Audited
EQUITY AND LIABILITIES			
<i>Shareholders' funds</i>			
Share capital	1,051.35	697.50	1,051.35
Reserves and surplus	2,838.02	414.67	2,536.91
	3,889.37	1,112.17	3,588.26
<i>Non-current liabilities</i>			
Long-term borrowings	-	-	-
Deferred tax liabilities (net)	4.66	(24.11)	4.75
Other long-term liabilities	89.11	83.92	-
Long-term provisions	198.02	170.20	156.55
	291.79	230.01	161.30
<i>Current liabilities</i>			
Short-term borrowings	38.55	178.31	106.33
Trade payables	-	-	-
Total outstanding dues of micro enterprises and	-	-	-
Total outstanding dues of creditors other than	470.66	493.23	737.86
Other current liabilities	299.30	295.71	423.20
Short-term provisions	183.65	244.50	158.51
	992.16	1,211.75	1,425.90
Total	5,173.32	2,553.93	5,175.46
ASSETS			
<i>Non-current assets</i>			
Property, Plant and Equipment			
Tangible assets	1,646.38	1,624.00	1,596.40
Intangible assets	123.81	53.57	104.38
Capital work-in-progress	137.48	35.19	123.09
Deferred tax Assets (net)	-	-	-
Long-term loans and advances	291.54	107.15	140.80
Non-current Investment	9.02	7.00	488.13
	2,208.23	1,826.91	2,452.80
<i>Current assets</i>			
Inventories	154.47	128.77	150.06
Trade receivables	399.34	267.72	355.86
Cash and cash equivalents	1,967.51	134.16	256.09
Short-term loans and advances	364.64	192.85	57.31
Other current assets	79.13	3.52	1,903.34
	2,965.09	727.02	2,722.66
Total	5,173.32	2,553.93	5,175.46

As per our report of even date attached.

For A A Mohare and Co.

FRN 114152W


Amit Mahore
Partner


Membership No. 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRWRL5094

For Vaidya Sane Ayurved Lab Limited




Rohit Sane

MD & CEO

DIN: 00679851

Place : Thane

Date : 10/11/2022



Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)

FI No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Cash flow statement for the period ended 30-Sep-2022

(Rupees in Lakhs)

	For the half year ended 30-Sep-2022	For the half year ended 30-Sep-2021	For the year ended 31-Mar-2022
Cash flows from operating activities			
Profit before tax	400.33	132.72	476.39
Adjustments to reconcile net profit to net cash and cash equivalents used in operating activities			
Depreciation and amortisation expense	115.53	117.45	228.57
Finance Cost	11.30	10.88	20.18
Interest income on bank deposits	(53.24)	(0.10)	(14.69)
Prior Period Adjustment	-	-	(1.49)
	473.92	260.95	708.96
Change in operating assets and liabilities			
(Increase)/Decrease in inventory	(4.41)	32.72	11.43
(Increase)/Decrease in accounts receivable	(43.48)	(3.88)	(92.02)
(Increase)/Decrease in other current assets	1,824.20	0.66	(1,758.86)
(Increase)/Decrease in other Non current assets	-	-	-
Decrease/(Increase) in long term and short term advances	(458.07)	1.91	(36.50)
(Decrease)/Increase in Other Long Term Liabilities	89.11	-	-
(Decrease)/Increase in accounts payable	(267.20)	(124.92)	63.08
(Decrease)/Increase in other current liabilities	(123.90)	(134.54)	(90.97)
(Decrease)/Increase in Long-term and Short-term provisions	66.61	44.74	1.74
Cash flow from operations	1,556.78	77.64	(1,193.14)
Direct taxes paid	99.30	(17.25)	(119.14)
Net cash flow from operating activities	1,457.48	60.39	(1,312.28)
Cash flows from investing activities			
Purchase of tangible/intangible assets	(247.97)	(76.61)	(317.20)
Proceeds from sale of tangible/intangible assets	48.65	-	18.36
Purchase of current investments	479.11	1.00	(487.13)
Net cash used in investing activities	279.79	(75.61)	(785.97)
Cash flows from Investing activities			
Right Issue	-	-	76.72
Share Premium received	-	-	1,910.81
2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the	-	-	277.12
Short Term Loan Repayment	(67.78)	76.68	4.70
Long Term Loan Repayment	-	-	-
Interest paid	(11.30)	(10.88)	(20.18)
Interest Received	53.24	0.10	14.69
Cash flows from financing activities	(25.84)	65.90	2,263.86
Net (decrease)/ increase in cash and cash equivalents	1,711.42	50.68	165.61
Cash and cash equivalents at the beginning of the year	256.09	90.48	90.48
Cash and cash equivalents at the end of the year	1,967.51	141.16	256.09
Cash and cash equivalents comprise of			
Cash on hand	10.08	14.14	28.40
Balances with banks in current accounts	1,957.43	127.02	227.69
Total	1,967.51	141.16	256.09

As per our report of even date attached.

For A A Mohare and Co.
FRN 114152W



Amit Mahore
Partner

Membership No. 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRWRL5094

For Vaidya Sane Ayurved Lab Limited


[Signature]

Rohit Sane
MD & CEO

DIN: 00679851

Place : Thane



Date : 10/11/2022



SEGMENT REPORTING - SEPT 2022

(Rs. In Lakhs)

Particulars	Hospital Activity			Sale of Product Activity			Common/ Unallocable			Total		
	SEP 2022	SEP 2021	2021-22	SEP 2022	SEP 2021	2021-22	SEP 2022	SEP 2021	2021-22	SEP 2022	SEP 2021	2021-22
REVENUE												
Segment Revenue	917.85	676.99	1,542.03	2,785.01	1,906.21	4,463.94	849.87	573.21	1,437.20	4,552.73	3,156.40	7,443.17
RESULT												
Other Segment Revenue	-	-	-	-	-	-	82.51	0.10	33.94	82.51	0.10	33.94
Material Consumed (Including direct Exp.)	193.04	130.27	246.00	1,113.41	809.12	1,863.96	-	4.74	17.93	1,306.46	944.12	2,127.88
Corporate Expenses	424.21	347.12	824.28	-	-	-	2,377.41	1,604.20	3,801.30	2,801.62	1,951.33	4,625.58
Operating Profit	300.59	199.59	471.75	1,671.60	1,097.09	2,599.98	(1,445.04)	(1,035.64)	(2,348.09)	527.16	261.05	723.64
Interest Cost	-	-	-	-	-	-	11.30	10.88	20.18	11.30	10.88	20.18
Depreciation	-	-	-	-	-	-	115.53	117.45	228.57	115.53	117.45	228.57
Income Taxes	-	-	-	-	-	-	99.30	17.25	119.14	99.30	17.25	119.14
Deferred Tax Provision	-	-	-	-	-	-	(0.08)	(20.01)	8.85	(0.08)	(20.01)	8.85
Net profit	300.59	199.59	471.75	1,671.60	1,097.09	2,599.98	(1,671.09)	(1,161.22)	(2,724.84)	301.11	135.47	346.89
OTHER INFORMATION												
Segment Assets	1,050.06	650.50	1,076.62							1,050.06	650.50	1,076.62
Unallocate Corporate Assets							4,123.26	1,927.53	4,094.08	4,123.26	1,927.53	4,094.08
Total Assets	1,050.06	650.50	1,076.62				4,123.26	1,927.53	4,094.08	5,173.32	2,578.03	5,170.70
Segment Liabilities	108.74	93.35	137.89							108.74	93.35	137.89
Unallocate Corporate Liabilities							5,064.58	2,484.68	5,032.81	5,064.58	2,484.68	5,032.81
Total Liabilities	108.74	93.35	137.89				5,064.58	2,484.68	5,032.81	5,173.32	2,578.03	5,170.70
Capital Expenditure							199.33	76.61	293.53	199.33	76.61	293.53
Depreciation							115.53	117.45	228.57	115.53	117.45	228.57
Non Cash Expenditure other than Depreciation							(8.74)	(9.09)	(34.77)	(8.74)	(9.09)	(34.77)





A. A. MOHARE & CO.
CHARTERED ACCOUNTANTS

1/3, Shree Vivekanand CHS Ltd.,
Guru Mandir Road, Saraswat Colony,
Dombivli (East) 421 201.
M : 9223 543 842 / LL : 0251 - 2473000
Email : amit@aamco.in

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO
THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTERIES LIMITED**


To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **VAIDYA SANE AYURVED LABROTERIES LIMITED** (the "Company" or "Parent") and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), and its share of the net profit after tax for the half year ended September 30, 2022 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement of Consolidated interim financial information based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity:


Sr. No.	Name of the Subsidiary	No. of Shares	Face Value	Value per Share paid	% holding in Company	Investment Value
1	Joint Healing Services Pvt Ltd	9900	10	10	99.00	99,000




5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at September 30, 2022, and of its results of operations and its cash flows for the half year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed .
6. There are no uncertainties arising from the COVID 19 pandemic on which our conclusion on the Statement is modified in respect of this matter unless specifically mentioned.

For A A Mohare & Co.

Chartered Accountants (FRN : 114152W)


CA Amit A Mohare
Partner



Membership No. : 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRVZI9985

Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)
 Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002
 (CIN No. : L73100PN1999PLC013509)

Consolidated Statement of profit and loss for the Half year ended 30-Sep-2022

		(Rupees in lakhs)
Particulars		For the Half Year Ended September 30, 2022
Revenue		
Revenue from operations		4,558.72
Other income		82.51
	Total revenue	4,641.23
Expenses		
Purchases of stock-in-trade		1,312.17
Change in inventory of finished goods, WIP and traded goods		(5.72)
Employee benefit expenses		1,083.80
Finance costs		11.30
Depreciation and amortisation expense		115.53
Other expenses		1,751.33
	Total expenses	4,268.41
Profit / (loss) before prior period adjustments & tax.		372.82
Prior period adjustments		
Profit / (loss) before extraordinary items and tax		372.82
Extraordinary items		
Profit / (loss) before tax		372.82
Tax expense		
Current tax		99.30
Deferred tax (expense)/income		(0.08)
Profit for the year		273.60
Profit / (loss) Share of Minority Interest		(0.27)
Profit / (loss) Share of Owner		(27.10)
Earnings per equity share		
[Nominal value per share Rs. 10 (PY. 2021-22 - Rs.10)]		
Basic		2.60
Diluted		2.60

Notes :

- The above financial results for the half year ended September 30, 2022 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 10th NOV, 2022
- As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid un-audited financial results for the half year ended 30th SEP 2022, which were also approved by the Audit Committee and Board at their meeting held on Thursday, 10th NOV, 2022.
- The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- As per MCA Notification Wited 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adapted IND-AS for preparation of financial results.
- The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below.

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	838.08	761.92
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1211.06	761.92

6) The losses applicable to the minority in a consolidated subsidiary may exceed the minority interest in the equity of the subsidiary. The excess, and any further losses applicable to the minority, are adjusted against the majority interest except to the extent that the minority has a binding obligation to, and is able to, make good the losses. If the subsidiary subsequently reports profits, all such profits are allocated to the majority interest until the minority's share of losses previously absorbed by the majority has been recovered.

7) Being a first year of consolidated financial statements comparative figures are not given.

As per our report on even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mohare

Partner

Membership No. 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRVZ19985

For Vaidya Sane Ayurved Lab Ltd

Rohit Sane

MD & CEO

DIN: 00679851

Place : Thane

Date : 10/11/2022

Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Consolidated Balancesheet as at 30-Sep-2022

(Rupees in lakhs)

	As at 30-Sep-22
EQUITY AND LIABILITIES	
<i>Shareholders' funds</i>	
Share capital	1,051.35
Reserves and surplus	2,810.51
	3,861.86
<i>Non-current liabilities</i>	
Long-term borrowings	0.00
Deferred tax liabilities (net)	4.66
Other long-term liabilities	89.12
Long-term provisions	198.02
	291.80
<i>Current liabilities</i>	
Short-term borrowings	38.55
Trade payables	
Total outstanding dues of micro enterprises and small enterprises; and	0.00
Total outstanding dues of creditors other than micro enterprises and small	467.99
Other current liabilities	301.57
Short-term provisions	183.78
	991.89
Total	5,145.55
ASSETS	
<i>Non-current assets</i>	
Property, Plant and Equipment	
Tangible assets	1,646.38
Intangible assets	123.81
Capital work-in-progress	137.48
Deferred tax Assets (net)	
Long-term loans and advances	292.54
Non-current Investment	8.03
	2,208.24
<i>Current assets</i>	
Inventories	155.77
Trade receivables	366.44
Cash and cash equivalents	1,971.32
Short-term loans and advances	364.64
Other current assets	79.14
	2,937.31
Total	5,145.55

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mahore
Partner

Membership No. 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRVZ19985

For Vaidya Sane Ayurved Lab Ltd


Rohit Sane

MD & CEO

DIN: 00679851

Place : Thane

Date : 10/11/2022



Vaidya Sane Ayurved Lab Ltd (Erstwhile known as Vaidya Sane Ayurved Lab Pvt Ltd)

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Consolidated Cash flow statement for the half year ended 30-Sep-2022

(Rupees in lakhs)

	For the year ended 30-Sep-2022
Cash flows from operating activities	
Profit before tax	372.82
Adjustments to reconcile net profit to net cash and cash equivalents used in operating activities	
Depreciation and amortisation expense	115.53
Finance Cost	0.00
Interest income on bank deposits	(53.24)
	435.11
Change in operating assets and liabilities	
(Increase)/Decrease in inventory	(5.71)
(Increase)/Decrease in accounts receivable	(10.58)
(Increase)/Decrease in other current assets	1,824.19
(Increase)/Decrease in other Non current assets	0.00
Decrease/(Increase) in long term and short term advances	(459.06)
(Decrease)/Increase in Other Long Term Liabilities	89.12
(Decrease)/Increase in accounts payable	(269.87)
(Decrease)/Increase in other current liabilities	(121.63)
(Decrease)/Increase in Long-term and Short-term provisions	66.74
Cash flow from operations	1,548.31
Direct taxes paid	99.30
Net cash flow from operating activities	1,449.01
Cash flows from investing activities	
Purchase of tangible/intangible assets	(247.97)
Proceeds from sale of tangible/intangible assets	48.65
Purchase of current investments	481.09
Net cash used in investing activities	281.77
Cash flows from financing activities	
Short Term Loan Repayment	(67.78)
Long Term Loan Repayment	0.00
Interest paid	0.00
Interest Received	53.24
Cash flows from financing activities	(14.54)
Net (decrease)/ increase in cash and cash equivalents	1,716.23
Cash and cash equivalents at the beginning of the year	256.09
Cash and cash equivalents at the end of the year	1,972.32
Cash and cash equivalents comprise of	
Cash on hand	11.08
Balances with banks in current accounts	1,961.24
Total	1,972.32

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mahore
Partner

Membership No. 148601

Place : Thane

Date : 10/11/2022

UDIN : 22148601BCRV219985

For Vaidya Sane Ayurved Lab Ltd

Rohit Sane
MD & CEO

DIN: 00679851

Place : Thane

Date : 10/11/2022